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Abstract
Purpose/Objectives—To determine the effect that age at diagnosis has on fear of breast cancer 
recurrence and to identify the predictors of fear of recurrence using self-efficacy as a mediator.
Design—Cross-sectional survey.
Setting—Two university cancer centers and one cooperative group in the midwestern United 
States.
Sample—1,128 long-term survivors.
Methods—Survivors were eligible if they were aged 18–45 years (younger group) or 55–70 
years (older group) at cancer diagnosis, had received chemotherapy, and were three to eight years 
postdiagnosis. Fear of recurrence was compared between younger and older groups. Multiple 
regression analyses were used to test variables’ prediction of fear of recurrence and breast cancer 
survivor self-efficacy, as well as breast cancer survivor self-efficacy mediation effects.
Main Research Variables—Fear of recurrence, breast cancer survivor self-efficacy, and age at 
diagnosis.
Findings—Survivors diagnosed at a younger age had significantly higher fear of recurrence, as 
well as health, role, womanhood, death, and parenting worries. Perceived risk of recurrence, trait 
anxiety, and breast cancer reminders explained significant variance in fear of recurrence and breast 
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cancer survivor self-efficacy. Breast cancer survivor self-efficacy partially mediated the effects of 
variables on fear of recurrence.
Conclusions—The findings suggest that breast cancer survivor self-efficacy may have a 
protective effect for survivors who are younger at diagnosis and have higher perceived risk of 
recurrence, higher trait anxiety, and more breast cancer reminders. Oncology nurses already use 
the skills required to support self-efficacy. Additional research is needed to define and test breast 
cancer survivor self-efficacy interventions.
Implications for Nursing—Oncology nurses are in a key role to assess fear of recurrence and 
provide self-efficacy interventions to reduce it in breast cancer survivors. Strategies to efficiently 
address fear of recurrence to reduce psychological distress in survivorship follow-up care are 
warranted.
The American Cancer Society ([ACS], 2012) estimated that more than 2.6 million women in 
the United States are breast cancer survivors. With increasing early detection and more 
effective treatment, breast cancer survival rates continue to rise, making psychosocial 
consequences of breast cancer, such as fear of recurrence, a concern for many women 
(Ferrell, Grant, Funk, Otis-Green, & Garcia, 1998a; Northouse, 1981; Vickberg, 2001; 
Welch-McCaffrey, Hoffman, Leigh, Loescher, & Meyskens, 1989). For most breast cancer 
survivors, fear of recurrence is a life-long concern (Vickberg, 2001). The prevalence of fear 
of recurrence suggests that survivors and oncology professionals need research to describe 
the construct and its prevalence and then test interventions to help survivors manage this 
problem.
Several factors may be relevant to the study of fear of recurrence. For instance, past work 
has identified age at diagnosis as an important factor in psychological symptoms of breast 
cancer survivors (Hewitt, Greenfield, & Stovall, 2006). Other variables such as anxiety, 
knowledge of symptoms, and breast cancer reminders also have been identified (Vickberg, 
2001). In addition, self-efficacy demonstrates promise as a construct related to a woman’s 
ability to handle survivorship problems (Bandura, 1997). Self-efficacy specific to breast 
cancer survivorship is defined as perceived confidence in managing symptoms and concerns 
related to diagnosis and treatment of breast cancer. Survivorship literature identifies self-
efficacy as a mediator of symptom distress (Cunningham, Lockwood, & Cunningham, 1991; 
Lev, Paul, & Owen, 1999). The purpose of this research was to determine the effect that age 
at diagnosis has on fear of recurrence and identify the predictors of fear of recurrence using 
self-efficacy as a mediator.
Background
Fear of recurrence is a distressing problem for the majority of survivors (Bloom, Stewart, 
Chang, & Banks, 2004; de Haes, Curran, Aaronson, & Fentiman, 2003; Ferrell et al., 1998a; 
Härtl et al., 2003; Mast, 1998; Northouse, 1981; Welch-McCaffrey et al., 1989). It interferes 
with quality of life, enjoyment of life, and global sense of well-being (Cimprich, Ronis, & 
Martinez-Ramos, 2002; Spencer et al., 1999). In addition, a higher fear of recurrence is 
correlated with syndromes such as post-traumatic stress disorder in long-term survivors 
(Mehnert, Berg, Henrich, & Herschbach, 2009; Vickberg, 2003). In one study, fear of 
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recurrence was significantly greater than any other concern, including those related to long-
term effects of chemotherapy (Spencer et al., 1999).
Historically, fear of recurrence research has focused only on fear of the cancer returning 
(Ferrell, Dow, Leigh, Ly, & Gulasekaram, 1995; Härtl et al., 2003; Hilton, 1989; Kornblith et 
al., 2007; Mast, 1998; Northouse, 1981; Spencer et al., 1999). That approach is limited in 
that survivors’ perceptions about fear of recurrence rarely are unidimensional. For instance, 
Vickberg (2001) found that one component of fear of recurrence for many women concerned 
fear about returning to chemotherapy. Some qualitative research has identified additional 
components of fear of recurrence. For example, survivors report fear of recurrence because 
they have young children and worry that a recurrence will not allow them to parent as their 
children grow (Ferrell et al., 1996). As Vickberg (2001, 2003) explored global fear of 
recurrence and ongoing worries, she found that survivors had concerns about health, 
womanhood, work, and relationship roles, as well as death. The same view was reported by 
other researchers (van den Beukenvan Everdingen et al., 2008). Viewing fear of recurrence 
as a multidimensional construct will allow clinicians and researchers to tailor fear of 
recurrence interventions.
Antecedents
Age at diagnosis has been identified as an important covariate for fear of recurrence. 
Kornblith et al. (2007) found that survivors diagnosed at age 55 or younger had a higher fear 
of recurrence than those diagnosed at age 65 and older, whereas Cimprich et al. (2002) did 
not find differences in fear of recurrence in those diagnosed when younger than 45, aged 45–
65, and older than 65 years. Both studies had fairly small sample sizes. In addition to age at 
diagnosis, initial treatment may impact fear of recurrence, including type of surgery, use of 
radiation, and use of tamoxifen or aromatase inhibitors (Vickberg, 2001). Therefore, the 
current study was designed with distinct age groups and initial treatment was controlled by 
including those with chemotherapy.
Time since diagnosis is another potential variable related to fear of recurrence. Some studies 
only assessed survivors one year or less post-treatment (Spencer et al., 1999), whereas others 
assessed survivors ranging from a few months to a few years post-treatment (Cimprich et al., 
2002; Clayton, Mishel, & Belyea, 2006; Connell, Patterson, & Newman, 2006; Härtl et al., 
2003; Hilton, 1989; Mast, 1998; Spencer et al., 1999; Vickberg, 2003). Literature describing 
the relationship between time since diagnosis and fear of recurrence has been hampered by 
lack of variability in time since diagnosis, an issue that the current study addressed. Women 
eligible for this study were three to eight years from initial treatment. Therefore, the authors 
could address the relationship between time since diagnosis and fear of recurrence. Because 
a commonly accepted survivorship marker is five years postdiagnosis, the authors decided to 
include a range before and after this marker (e.g., three to eight years) to control for any 
differences in perception related to length of time since diagnosis.
Several variables that might act as predictors of fear of recurrence were identified in the 
literature and clinical practice. In this section, the authors will describe those additional 
variables, including perceived risk of recurrence, knowledge of someone with a recurrence, 
symptom bother, recurrence signs, trait anxiety, and breast cancer reminders.
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Perceived risk of developing cancer has been studied in the context of cancer worry in 
populations at high risk for cancer (Easterling & Leventhal, 1989; Loescher, 2003). 
Individuals who had a higher perceived risk of developing cancer reported greater cancer 
worry and reported more cancer worry in the presence of increased symptoms (Easterling & 
Leventhal, 1989). In qualitative research, women described knowing someone with a 
recurrence (including public figures) as a trigger for their own fear of recurrence (Vickberg, 
2001).
Little is known about the knowledge survivors have regarding symptoms of recurrence. The 
presence of breast cancer-related symptoms and non–breast cancer-related symptoms have 
been found to be associated with thoughts about recurrence (Clayton et al., 2006). Many 
survivors experience ambiguous symptoms, such as fatigue, and misinterpret these as signs 
that their cancer has recurred (Lee-Jones, Humphris, Dixon, & Hatcher, 1997). That may 
lead to behavioral responses such as repeated body checking, persistent requests for tests, 
and seeking repeated reassurance from healthcare providers during survivorship (Fredette, 
1995; Lee-Jones et al., 1997), as well as the tendency to obsess over symptoms (Figueiredo, 
Fries, & Ingram, 2004; Welch-McCaffrey et al., 1989).
Although trait anxiety has not been found to increase a woman’s risk of developing breast 
cancer (Aro et al., 2005), it has been associated with emotional and physical distress (Ferrell 
et al., 1998a; Hewitt, Herdman, & Simone, 2004). In women with early-stage breast cancer, 
trait anxiety has been associated with persistent distress for at least two years postdiagnosis 
(Bleiker, Pouwer, van der Ploeg, Leer, & Adér, 2000). Knowledge of the role of trait anxiety 
in fear of recurrence could help healthcare providers as they plan, support, and guide 
anxiety-reduction interventions.
Long-term survivors report the highest levels of fear of recurrence during healthcare-related 
visits, such as mammography appointments and visits to the healthcare team. Those routine 
follow-up appointments may coincide with their anniversary date of diagnosis, the most 
intense reminder of breast cancer (Spencer et al., 1999; Vickberg, 2003). Breast cancer 
survivor self-efficacy has been demonstrated to be significantly lower in women diagnosed 
at age 45 years and younger compared to women diagnosed at 55 years or older (Champion, 
Sledge, Ziner, Monahan, & Zho, 2010).
Self-Efficacy
Theories of emotion and self-efficacy are the basis of the theoretical framework that guides 
this study. Emotion theorists posit fear is an emotional response to stimuli perceived as 
harmful (Lazarus, 1991; Ohman, 2000). Self-efficacy is the confidence to produce desired 
effects by one’s own actions (Bandura, 1997). In this study, self-efficacy is defined as one’s 
confidence in the ability to manage symptoms and emotions related to having breast cancer, 
including the ability to ask for help, know how and when to report symptoms, and do what is 
important after breast cancer treatments are completed. Building on the identified antecedent 
variables and breast cancer survivor self-efficacy, two research questions were proposed: (a) 
Does fear of recurrence and related subscales differ between survivors diagnosed at younger 
and older ages, and (b) does breast cancer survivor self-efficacy mediate the relationship 
between antecedent variables and fear of recurrence?
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Methods
Design and Sample
This study used a cross-sectional survey design to collect data within a larger breast cancer 
survivor quality-of-life study. The larger study was designed with a distinct age gap, leaving 
out women diagnosed from ages 46–54 years, to test differences between women diagnosed 
with breast cancer at a young age (45 or younger) and women diagnosed at an older age 
(55–70); this gap was to allow potentially smaller differences to be detected. A theoretical 
framework proposing relationships among fear of recurrence, as well as research-identified 
variables, guided data collection and analysis. Surveys were mailed to participants’ homes 
after they provided written informed consent.
A total of 1,128 survivors were included in the study. Survivors were eligible if they had 
been diagnosed from age 18–45 years for the younger group or age 55–70 years for the older 
group. Eligibility included chemotherapy as part of their treatment and being three to eight 
years from initial diagnosis. A total of 744 younger and 937 older eligible survivors were 
contacted and 505 (68%) younger and 623 (67%) older survivors agreed to participate (see 
Table 1).
Data Collection
Women were recruited from three settings: two Midwestern university cancer centers and 
one cooperative oncology group. Recruitment proceeded according to Health Insurance 
Portability and Accountability Act of 1996 guidelines after Indiana University-Purdue 
University Indianapolis institutional review board approval. Current healthcare providers 
asked eligible survivors if they were willing to be approached by the study staff. If survivors 
agreed, healthcare providers sent survivors’ contact information to the study staff, who then 
contacted interested survivors by phone or in person. Written informed consent was 
obtained.
Instruments
Several instruments were used to measure variables hypothesized to affect fear of 
recurrence. All instruments were tested for content validity by five quality-of-life researchers 
and three clinical breast cancer experts, with both groups assessing the item-Content Validity 
Index ([item-CVI] as 1, resulting in an excellent modified kappa statistic [k*] of 1). Twelve 
survivors confirmed face validity.
Demographic variables, including age at diagnosis, were measured by questions asked as 
part of the cross-sectional survey. Perceived risk of recurrence was measured by one item: “I 
will have a breast cancer recurrence at some time in my life,” with a five-point Likert-type 
response scale ranging from 1 (strongly disagree) to 5 (strongly agree). The single item is 
similar to one previously used to assess perceived risk of developing cancer for those at high 
risk (Loescher, 2003).
Knowledge of someone with a recurrence included a single dichotomous item asking 
whether the survivor knew anyone with a breast cancer recurrence. Qualitative research has 
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identified this as a key component of fear of recurrence. The single item was developed for 
the current study from qualitative literature identifying this concept (Vickberg, 2001).
Knowledge of Recurrence Signs is a scale that was developed based on the American 
Society of Clinical Oncology’s (2001) common clinical symptoms of recurrence. It includes 
11 items: six common clinical symptoms of recurrence and five symptoms not associated 
with recurrence. The six common clinical symptoms of recurrence were (a) bone pain or 
tenderness lasting more than two weeks; (b) skin rashes, redness, or swelling on breast(s), 
scar, or chest area; (c) new lumps or other changes in breast(s); (d) chest pain and shortness 
of breath; (e) persistent abdominal fullness, discomfort, or pain; and (f) changes in weight, 
particularly weight loss. The five symptoms not associated with recurrence were fever, 
frequent colds, flu-like symptoms, persistent hot flashes, and changes in sleep patterns. 
Participants were asked to indicate whether the item was a sign of breast cancer recurrence 
(i.e., true or false). Correct responses were summed for a total score, with a higher score 
indicating greater knowledge. Internal consistency reliability (Kuder-Richardson formula 
20) was 0.77.
Ridner’s Symptom Bother Scale has items to measure the presence and bother of common 
symptoms associated with arm and chest wall sensations on the mastectomy or lumpectomy 
side, which were extracted from the Lymphedema Symptom Intensity and Distress Scale–
Arm (LSID-A) (Ridner & Dietrich, 2010). A modified version of 12 symptoms, including 
arm feels heavy, hand swollen, arm swollen, chest swollen, arm feels tight, arm feels hard, 
numbness, breast pains, skin crawls, change sleeping position because of symptom, and 
related bother, was used for this study (Cronbach alpha = 0.88). The weighted global index 
of symptom burden in two studies using the full LSID-A scale had a Cronbach alpha of 0.95 
(Ridner & Dietrich, 2010).
The Trait Anxiety Inventory, a 20-item trait sub-scale, measures how anxious people feel 
in general (Spielberger, Gorsuch, Lushene, Vagg, & Jacobs, 1983). Median test-retest 
correlations for the trait anxiety inventory ranged from 0.7–0.77. Concurrent validity with 
other measures of trait anxiety were high, ranging from 0.73–0.85 (Spielberger et al., 1983). 
In a pretest, post-test design study of 123 breast cancer survivors, the alpha was reported as 
0.92 pretest and 0.94 post-test (Fogarty, Curbow, Wingard, McDonnell, & Somerfield, 
1999). In the current sample, Cronbach alpha reliability was 0.93.
Eight items based on survivor accounts of triggers of fear of recurrence (Ferrell et al., 1996; 
Vickberg, 2001) were provided, including (a) breast cancer fundraising events, (b) helping 
other women with breast cancer through support groups or individuals calls, (c) my annual 
date of diagnosis, (d) my mammogram, (e) new symptoms I do not understand, (f) hearing 
of someone I know who has had a recurrence, (g) routine oncologist appointment, and (h) 
having blood drawn for tests or IV. An additional choice, “other,” allowed survivors to self-
identify triggers not on the list. Survivors identified the amount of time in the last month that 
the reminders caused them to think about breast cancer. The nine-item, Likert-type scale 
ranged from 1 (not at all) to 5 (all or most of the time), with 0 = not applicable. Responses 
were summed. For construct validity, Pearson r correlations were used. The Breast Cancer 
Reminders scale was significantly correlated with the Impact of Events Scale-Revised (IES-
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r) (r = 0.41, p < 0.001); all IES-r subscales, including avoidance (r = 0.28, p < 0.001), 
intrusion (r = 0.43, p < 0.001), and hyper-arousal (r = 0.35, p < 0.001); and the fear of 
recurrence index of the Concerns About Recurrence Scale (CARS) (r = 0.39, p < 0.001) 
(Ziner, 2008).
The Breast Cancer Survivor Self-Efficacy Scale was developed for the larger study and 
measured survivors’ confidence in dealing with concerns related to breast cancer after 
treatment. The scale used a 14-item, five-point Likert-type scale with responses ranging 
from 1 (strongly disagree) to 5 (strongly agree). Items included issues such as being able to 
ask for help when problems arise, dealing with physical symptoms, and emotional issues 
from having breast cancer. Responses were summed for a total score. Construct validity was 
supported with a confirmatory structural equation model (Champion et al., 2011). Cronbach 
alpha reliability was 0.93 in this sample.
Fear of recurrence was measured using CARS (Vickberg, 2003). CARS is a two-part 
instrument developed for survivors assessing overall fear of recurrence (fear of recurrence 
index) and worries related to recurrence. Sub-scales include death worries (2 items), health 
worries (11 items), role worries (6 items), and womanhood worries (7 items). A fifth 
subscale, parenting worries (2 items), was added on the advice of younger survivors who 
reviewed the measures prior to the current study and was approved by Vickberg (personal 
communication, July 6, 2004). All subscales employed a five-point Likert-type response 
format ranging from 0 (not at all) to 4 (all or most of the time) (Vickberg, 2003). The 
internal consistency reliability of the subscales ranged from 0.81–0.93.
Data Analysis
SPSS®, version 14, was used for all analyses. Independent sample t tests were used to 
compare differences in fear of recurrence among younger and older survivors. Multiple 
linear regression analyses were used to test the association between each variable and fear of 
recurrence while adjusting for the effects of other variables. The full sample of 1,128 was 
available for the independent t test; however, because the authors chose not to impute 
missing data, the SPSS program included a reduced sample of 1,076 within the multiple 
regression analysis.
Findings
A total of 1,128 survivors were included in the analysis, with about 45% being diagnosed at 
45 or younger and 55% being diagnosed from age 55–70. A majority was Caucasian (92%), 
married (75%), had at least some college education (64%), and had a household income of 
$50,000 or more (62%). All women were treated with chemotherapy and had some type of 
surgery; 47% had a lumpectomy, 51% had a mastectomy, and about 2% had both.
Research Question 1 tested for differences between the younger and older survivors on the 
CARS fear of recurrence index and subscales. Overall, younger women experienced more 
fear and worry than older women. All t values for independent tests were significant and 
ranged from 7.7–15.4 (see Table 2). Women diagnosed at a younger age had a significantly 
higher mean fear of recurrence index and higher mean worries for health, role, womanhood, 
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death, and parenting compared to women diagnosed at an older age. The greatest difference 
was seen with the parenting worries subscale.
Research Question 2 sought to determine the mediation effect of breast cancer survivor self-
efficacy on antecedent variables in predicting fear of recurrence. Multiple linear regressions 
were used to test the relationships of the antecedent variables, breast cancer survivor self-
efficacy, and fear of recurrence using the Baron and Kenny (1986) method. If the 
unstandardized regression coefficients changed once breast cancer survivor self-efficacy was 
added to the analysis, the methods suggested by Frazier, Tix, and Barron (2004) were used 
to test for significance of the mediation.
The antecedents first were regressed on fear of recurrence. Variables negatively associated 
with fear of recurrence included age at diagnosis (p = 0.001), perceived risk of recurrence (p 
= 0.001), trait anxiety (p = 0.001), and breast cancer reminders (p = 0.001). Antecedents 
explained 38% of the variance in fear of recurrence (see Table 3). Other predictors were not 
significant.
As a second step, breast cancer survivor self-efficacy was regressed on the antecedents. 
While controlling for other predictors in the model, age at diagnosis was nonsignificantly 
related to breast cancer survivor self-efficacy. Higher perceived risk of recurrence (p = 0.07), 
knowledge of someone with a recurrence (p = 0.004), symptom bother (p < 0.001), trait 
anxiety (p < 0.001), and breast cancer reminders (p = 0.014) all were related inversely to 
breast cancer survivor self-efficacy.
As a third step, fear of recurrence was regressed on the mediating variable breast cancer 
survivor self-efficacy (see Table 4). Breast cancer survivor self-efficacy explained about 18% 
(p < 0.001) of the variance in fear of recurrence. Higher breast cancer survivor self-efficacy 
predicted lower fear of recurrence.
Finally, fear of recurrence was regressed on antecedent variables and breast cancer survivor 
self-efficacy. Mediation is indicated when the strength of the relationship between the 
antecedents and outcome variable is reduced when the mediator enters the analysis (Baron & 
Kenny, 1986). Therefore, fear of recurrence was regressed on antecedents plus breast cancer 
survivor self-efficacy (see Table 5). About 18% variance was accounted for by antecedents 
and self-efficacy on fear of recurrence (p = 0.001).
The strength of the relationship among antecedents and fear of recurrence changed 
significantly when breast cancer survivor self-efficacy was added to the analysis. For each 
coefficient, a decrease in the regression coefficient once breast cancer survivor self-efficacy 
was added to the analysis was tested for significance of change (Frazier et al., 2004). The 
coefficient change was significant (p = 0.05) for age at diagnosis, perceived risk of 
recurrence, trait anxiety, and breast cancer reminders. Specifically, the standardized 
regression coefficients became smaller (less strength) for age at diagnosis (−1.9 to −1.8), 
perceived risk of recurrence (2.46–2.34), trait anxiety (0.13–0.077), and breast cancer 
reminders (0.215–0.205). Breast cancer survivor self-efficacy is a significant partial 
mediator of the relationships between fear of recurrence and age at diagnosis, perceived risk 
of recurrence, trait anxiety, and breast cancer reminders. Breast cancer survivor self-efficacy 
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was significantly related to fear of recurrence with a regression coefficient of −0.183 (p < 
0.001), which explained about 3% of the unique variance in fear of recurrence. Higher breast 
cancer survivor self-efficacy predicted lower fear of recurrence.
Conclusions
The authors first sought to determine whether a difference existed between breast cancer 
survivors who were diagnosed at age 45 years or younger compared to those diagnosed at 
55–70 years in relation to fear of recurrence. While controlling for time since diagnosis and 
treatment, survivors diagnosed in the younger age group had higher fear of recurrence and 
related worries than survivors in the older age group, which is consistent with previous 
research that reported younger age was associated with more troublesome thoughts of 
recurrence indirectly through the relationship between higher symptom bother and younger 
age (Clayton et al., 2006). Other researchers have described a relationship between younger 
age at diagnosis and higher fear of recurrence (Härtl et al., 2003; Hilton, 1989; Mast, 1998; 
Vickberg, 2003).
The findings suggest women diagnosed at a younger age may be at higher risk for fear of 
recurrence in general and of specific worries about fear of recurrence. Age group at 
diagnosis was considered an antecedent variable in the current study and younger age at 
diagnosis predicted higher fear of recurrence, but not breast cancer survivor self-efficacy. 
Other antecedent variables, including perceived risk of recurrence, trait anxiety, and breast 
cancer reminders, predicted fear of recurrence and breast cancer survivor self-efficacy. The 
relationship of those antecedent variables with fear of recurrence was mediated by breast 
cancer survivor self-efficacy. Of those variables, anxiety and thoughts of breast cancer have 
been explored by others. A study by Mehnert et al. (2009) found that anxiety was related to 
moderate to high levels of fear of recurrence. After breast cancer is diagnosed, anxiety often 
has been considered a part of psychosocial distress, a quality-of-life domain that includes 
fear of recurrence (Ferrell et al., 1998a; Hewitt et al., 2004).
Women with more thoughts about breast cancer triggered by breast cancer reminders had 
higher fear of recurrence. That finding was supported by qualitative results in the literature 
(Ferrell et al., 1998b; Vickberg, 2001) and research with older survivors (Clayton et al., 
2006). Events that trigger fear of recurrence often were associated with healthcare-related 
activities such as mammograms, clinic visits, and blood work. Being cognizant of those 
triggers is an important consideration for survivors and healthcare providers.
Three antecedents did not impact fear of recurrence: knowing someone with a recurrence, 
knowledge of recurrence signs, and symptom bother. However, other qualitative reports by 
survivors described knowing someone with a recurrence as a trigger for their own fear of 
recurrence (Vickberg, 2001). Although the current study’s findings indicated that most 
survivors had a fairly accurate knowledge of recurrence signs, this knowledge was not 
correlated with fear of recurrence; higher survivors’ knowledge of recurrence signs alone did 
not seem to reduce fear of recurrence. Finally, symptom bother was not related to fear of 
recurrence, although the presence of breast cancer-related symptoms and non–breast cancer-
related symptoms have been associated with thoughts of recurrence (Clayton et al., 2006). 
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The difference in the current study may have to do with the type of symptoms reported. In 
this study, symptoms were not related to clinical signs of breast cancer, but instead were 
clinical signs related to breast cancer treatment complications (e.g., numbness, discomfort).
Survivors with higher breast cancer survivor self-efficacy had lower fear of recurrence. In 
addition, breast cancer survivor self-efficacy mediated the relationship between younger age 
at diagnosis, higher perceived risk of recurrence, higher trait anxiety, more breast cancer 
reminders, and higher fear of recurrence, indicating that breast cancer survivor self-efficacy 
may have a protective effect. Self-efficacy for coping with cancer (Merluzzi, Nairn, Hegde, 
Martinez Sanchez, & Dunn, 2001) found that patients with higher cancer self-efficacy 
during treatment and immediately after experienced higher general quality of life, less 
anxiety, and a greater sense of well-being.
Limitations
Although having clearly delineated age at diagnosis groups was beneficial for the 
comparison of fear of recurrence in younger and older survivors, conclusions cannot be 
drawn about fear of recurrence in survivors diagnosed from ages 46–54, as these women 
were not included in the study. The sample primarily included women who were Caucasian 
and English speaking, so the results may not generalize to non-Caucasian or non-English 
speaking survivors. Moreover, the study was a cross-sectional survey, which does not allow 
any conclusions about fear of recurrence over time.
Implications for Nursing
The study’s findings indicate that breast cancer survivor self-efficacy may be an important 
construct to use in interventions addressing fear of recurrence in breast cancer survivors. 
Providing breast cancer survivors with the knowledge and skills to deal with the symptoms 
resulting from breast cancer may help decrease fear of recurrence as well as anxiety and 
perceived risk of recurrence.
Oncology and family practice nurses can support survivors by validating that fear of 
recurrence is an ongoing concern for the majority of survivors and that survivors diagnosed 
at a younger age are at a higher risk for fear of recurrence and worries about health, life 
roles, womanhood issues, and parenting. Nurses can educate survivors to anticipate common 
fear of recurrence triggers. For example, the current study’s findings and qualitative reports 
discuss healthcare provider visits as triggers for higher fear of recurrence. Nurses can tell 
survivors that experiencing fearful responses to upcoming healthcare provider visits is 
normal and can collaborate with survivors to develop a plan to reduce any quality-of-life 
interference these understandable fears might cause.
Oncology nurses already possess and use the skills required to build and sustain self-
efficacy. According to Bandura (1997), self-efficacy is accomplished through mastery, 
vicarious experiences, verbal persuasion, and emotional arousal. Nurses coach their patients 
with information and skill-building to achieve mastery. Nurses also use verbal persuasion 
(e.g., “You can do this!”) to help patients manage symptoms and emotions. In addition, 
nurses provide knowledge of what is normal among patients’ experiences and refer to trusted 
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support networks that provide vicarious experiences. Emotional arousal may be linked to the 
ability to act; therefore, nurses assess their patients for emotions that can help motivate them 
to take needed action or for higher emotional responses that may cause patients to avoid 
actions and thereby identify those patients who need a referral for more extensive 
intervention. Therefore, once research provides the information on how survivors build 
breast cancer survivor self-efficacy, nurses will be prepared immediately to translate this 
information to practice.
Although the results of this research provide possibilities for intervention, additional 
research is needed. First, interventions must be defined and tested to develop and strengthen 
breast cancer survivor self-efficacy. Second, researchers must establish how survivors 
determine their risk of recurrence and how perceived risk of recurrence relates to actual risk 
of recurrence (e.g., stage at diagnosis), thus identifying interventions to normalize survivors’ 
perceived risk of recurrence. Finally, breast cancer survivor self-efficacy reduced the effect 
of younger age at diagnosis on fear of recurrence, so understanding which other variables or 
combinations of variables share variance with age at diagnosis warrants additional 
exploration. Identifying one or more variables that influence that relationship could add to 
how fear of recurrence is managed, particularly in women diagnosed at younger ages.
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Table 1
Demographic Characteristics
Characteristic n %
Age at diagnosis (years)
 45 or younger 505 45
 55–70 623 55
Race
 Caucasian 1,042 92
 African American 43 4
 American Indian 10 1
 Other or mixed race 33 3
Income ($)
 Less than 15,000 56 5
 15,001–30,000 138 12
 30,001–50,000 210 19
 50,001–75,000 248 22
 75,001–100,000 194 18
 100,001–150,000 131 12
 150,001–200,000 64 6
 More than 200,000 49 4
 Don’t know 20 1
 Unreported 18 2
Marital status
 Married 837 74
 Divorced 80 7
 Widowed 104 9
 Single 89 8
 Unreported 18 2
Highest education
 Graduate or professional degree 211 19
 Some graduate school 56 5
 Four years of college 157 14
 Two years of college 89 8
 Some college 192 17
 Technical or trade school 103 9
 High school 269 24
 Some high school 32 3
 Elementary school 2 < 1
 Unreported 17 2
Type of surgery
 Mastectomy 574 51
 Lumpectomy 532 47
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Characteristic n %
 Both 19 2
 Unreported 3 < 1
Time since diagnosis (years)
 3 47 4
 4 164 15
 5 252 22
 6 240 21
 7 234 21
 8 160 14
 9 31 3
N = 1,128
Note. Because of rounding, not all percentages total 100.
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Table 4
Regression of Fear of Recurrence on Breast Cancer Survivor Self-Efficacy
Variable Value
Standardized beta −0.42
Standard error 0.02
t test −15.61
p < 0.001
Zero-order correlation −0.42
Semipartial correlation −0.42
Semipartial % variance 17.6
N = 1,126
Note. F(1, 1124) = 243.6, p < 0.001
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